Real-life experience of the first patients treated with Bempedoic acid in 2 lipid clinics of Belgium
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
One study focusing on HIV reported HIV in 100% of patients.
“and one study focusing on HIV reported HIV in 100% of patients [28].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [28]
Gout was reported in approximately 2% to 3% of patients (2 of 83 to 2 of 65) on bempedoic acid.
“Across studies that reported specific AEs, bempedoic acid was generally well tolerated, with myalgia reported in 6% of patients (12 of 200) [39]; gout in approximately 2% to 3% of patients (2 of 83 to 2 of 65) [28,29]; elevated liver enzymes in 1.2% to 3% of patients (1 of 85 to 6 of 200) [28,39]; cholelithiasis in 2.7% of patients (2 of 65) [29]; and new-onset diabetes in 2% of patients (4 of 200”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [28]
Among the few studies reporting treatment discontinuation (n = 4), rates ranged from 9% to 36% across heterogeneous populations with mixed prevention status, varying degrees of statin intolerance, and different background LLTs.
“Among the few studies reporting treatment discontinuation (n = 4) [23,28,30,40], rates ranged from 9% to 36% across heterogeneous populations with mixed prevention status, varying degrees of statin intolerance, and different background LLTs.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [28]
Elevated liver enzymes were reported in 1.2% to 3% of patients (1 of 85 to 6 of 200) on bempedoic acid.
“Across studies that reported specific AEs, bempedoic acid was generally well tolerated, with myalgia reported in 6% of patients (12 of 200) [39]; gout in approximately 2% to 3% of patients (2 of 83 to 2 of 65) [28,29]; elevated liver enzymes in 1.2% to 3% of patients (1 of 85 to 6 of 200) [28,39]; cholelithiasis in 2.7% of patients (2 of 65) [29]; and new-onset diabetes in 2% of patients (4 of 200”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [28]
An increased incidence of gout was observed with bempedoic acid.
“An increased incidence of gout was observed with bempedoic acid [28,29]; higher discontinuation rates observed (up to 36%) [23,28,30,40] likely reflect the broader inclusion of patients with statin intolerance or LLT non-tolerance, although reasons for discontinuation were not consistently reported.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [28]
Higher discontinuation rates observed (up to 36%) likely reflect the broader inclusion of patients with statin intolerance or LLT non-tolerance.
“An increased incidence of gout was observed with bempedoic acid [28,29]; higher discontinuation rates observed (up to 36%) [23,28,30,40] likely reflect the broader inclusion of patients with statin intolerance or LLT non-tolerance, although reasons for discontinuation were not consistently reported.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [28]
In all-comer populations with mixed statin-intolerance and varied background LLTs, LDL-C reductions with bempedoic acid ranged from 18% to 42%.
“In all-comer populations with mixed statin-intolerance and varied background LLTs, LDL-C reductions also ranged from 18% to 42% [23,26,28,30,31,33,43].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [28]
Cites
Still being checked.
Cited by
Sorted by citations
Lipid clinic experience with bempedoic acid in three UK centres
Jakubowska, A., Al Hasani, W., Williams, J., MacMahon, Z., Balbas, B., Crook, M. A., Viljoen, A., Reynolds, T. M., & Wierzbicki, A. S. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2341870 · Cited by 5 · see citing works
Systematic literature review on the real-world effectiveness and safety of bempedoic acid
Cicero, A. F. G., Cannon, C. P., Gautam, R., Anwar, S., Ghatak, A., Sarnes, E., Powell, H. A., Chhabra, R., & Jawla, S. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100562 · Cited by 1 · see citing works
“…to initiation of bempedoic acid, patients had LDL-C levels ranging from 90 mg/dL to 146 mg/dL. Diabetes was present in 11% to 66% of patients [23,25,29,30,32,38, 39,41,42]; hypertension in 33% to 83% [23,25,29,30,32,39,42,44]; and one study focusing on HIV reported HIV in 100% of patients [28].”
Influential(2023) · Reactions Weekly · doi:10.1007/s40278-023-47147-8
Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort
Jiménez, D. L., Martínez‐Hervás, S., Martínez, N. L., Jericó, C. R., Martínez-Soriano, M. J., Royuela, M., Franco‐Moreno, A., Rodríguez-Carnero, G., Varona, J. F., Molinero, A. M., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.033
- Authors
- Demeure, F., Sperone, A., Snel, M., & Descamps, O.
- Affiliations
- CHU Dinant Godinne UCL Namur (BE)
- Hôpital de Jolimont (BE)
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2023-08
- Volume
- 379
- Pages
- S57-S58
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W4386267002
- Cited by
- 4
- References
- 0
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 1
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Atherosclerosis (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- bempedoic acid, ATP-citrate lyase inhibitor, LDL cholesterol lowering, hypercholesterolemia, uric acid, gout, creatinine elevation, lipid clinic, statin intolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
